Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Future Oncology (London, England)
|
February 15, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Marina C Garassino, Luis Paz-Ares, Rina Hui, et al.
Annals of Nuclear Medicine
|
August 11, 2018
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial
Michael J Seider, Stephanie L Pugh, Corey Langer, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 27, 2019
Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy
Amardeep S Grewal, Eun Jeong Min, Qi Long, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 10, 2012
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
Matthew G Fury, Eric Sherman, Donna Lisa, et al.
Nature Medicine
|
January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Advances in Radiation Oncology
|
July 6, 2023
Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
Jyotsna Natarajan, Nikhil Yegya-Raman, Timothy P Kegelman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 18, 2004
A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
Andy Trotti, Adam Garden, Padraig Warde, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 7, 2020
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
Jarrod D Predina, Andrew R Haas, Marina Martinez, et al.
The Lancet. Oncology
|
September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 4, 2008
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial
Minesh P Mehta, William R Shapiro, See C Phan, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Future Oncology (London, England)
|
February 15, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Marina C Garassino, Luis Paz-Ares, Rina Hui, et al.
Annals of Nuclear Medicine
|
August 11, 2018
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial
Michael J Seider, Stephanie L Pugh, Corey Langer, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 27, 2019
Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy
Amardeep S Grewal, Eun Jeong Min, Qi Long, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 10, 2012
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
Matthew G Fury, Eric Sherman, Donna Lisa, et al.
Nature Medicine
|
January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial
Yasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Advances in Radiation Oncology
|
July 6, 2023
Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
Jyotsna Natarajan, Nikhil Yegya-Raman, Timothy P Kegelman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 18, 2004
A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
Andy Trotti, Adam Garden, Padraig Warde, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 7, 2020
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
Jarrod D Predina, Andrew R Haas, Marina Martinez, et al.
The Lancet. Oncology
|
September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 4, 2008
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial
Minesh P Mehta, William R Shapiro, See C Phan, et al.
Page
of 11